Search
Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis. … Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago.
Anthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalIt is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Phenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.
Categories: Ammonium Ion Binding ActivitySynonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic … It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsProducts: Apixaban 1A Pharma 5 mg – Filmtabletten, Apixaban 1A Pharma 2,5 mg – FilmtablettenCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined. … [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.
Categories: Compounds used in a research, industrial, or household settingFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.
Synonyms: 4-OH-A